Antengene (HKG:6996) said the Center for Drug Evaluation of China's National Medical Products Administration endorsed a phase 3 study of ATG-022 in advanced gastric or gastroesophageal junction adenocarcinoma, according to a Thursday filing with the Hong Kong bourse.
The trial, called CLINCH-3, is expected to be initiated in China first and is planned as a multi-regional clinical trial.
The study is intended to support a future marketing approval application for ATG-022 as a monotherapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.